TrialThoracic cancer2021

SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study.

Lan Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.